Figure 5From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients Survival in gastric cancer patients according to UICC 7th edition, MTHFR A1298C AC versus AA/CC. Legend: Subgroup analysis for patients with adenocarcinoma of the stomach dependent on polymorphisms of MTHFR A1298C, comparing AC genoytpe to AA and CC genotype. Median Survival times: AA/CC not reached, AC 26.5 months, p = 0.002.Back to article page